Sulfatase-2 from cancer associated fibroblasts – an environmental target for hepatocellular carcinoma?
Conclusion: SULF2 derived from CAFs modulates glypican-3/β-catenin signalling, but also the HCC immun e TME, associated with tumour progression and therapy resistance via activation of the TAK1/IKKβ/NF-κB pathway. It is an attractive target for combination therapies for patients with HCC. (Source: Liver Cancer)
Source: Liver Cancer - July 13, 2022 Category: Cancer & Oncology Source Type: research
Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable Hepatocellular Carcinoma: Results From Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
Introduction The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab vs sorafenib as a first-line treatment in younger vs older patients with unresectable HCC.
Methods This global, phase 3, open-label, randomized clinical trial (IMbrave150) recruited patients aged ≥18 years with locally advanced metastatic or unresectable HCC, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and Child-Pugh class A liver function who had not previously received sy...
Source: Liver Cancer - July 13, 2022 Category: Cancer & Oncology Source Type: research
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
Conclusions: Our study confirms in a large and global population of patients with advanced HCC, not candidates for locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib. (Source: Liver Cancer)
Source: Liver Cancer - July 11, 2022 Category: Cancer & Oncology Source Type: research
REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study
Conclusions:
Our study confirms in a large and global population of patients wi th advanced HCC not candidate to locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib. (Source: Liver Cancer)
Source: Liver Cancer - July 11, 2022 Category: Cancer & Oncology Source Type: research
Discriminatory changes in circulating metabolites as a predictor of hepatocellular cancer in patients with MAFLD
Objectives:The burden of metabolic (dysfunction) associated fatty liver disease (MAFLD) is rising mirrored by an increase in hepatocellular cancer (HCC). MAFLD and its sequelae are characterised by perturbations in lipid handling, inflammation and mitochondrial damage. The profile of circulating lipid and small molecule metabolites with the development of HCC is poorly characterized in MAFLD and could be used in future studies as a biomarker for HCC.
Design:We assessed the profile of 273 lipid and small molecule metabolites by ultra ‐performance liquid chromatography coupled to high-resolution mass spectrometry (UPLC-MS...
Source: Liver Cancer - July 8, 2022 Category: Cancer & Oncology Source Type: research
APPLE News
Liver Cancer 2022;11:398 –398 (Source: Liver Cancer)
Source: Liver Cancer - July 5, 2022 Category: Cancer & Oncology Source Type: research
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma After First-Line Therapy: Expert Recommendations from Hong Kong, Singapore and Taiwan
This article evaluates the evidence and pro vides expert recommendations for the use of systemic therapies after first-line treatment in patients with advanced HCC.
Summary: Based on three virtual meetings held in early 2021, a team of 17 experts comprising oncologists, a hepatologist and a hepatobiliary surgeon from Hong Kong, Singapore and Taiwan reviewed available data about systemic treatments for HCC after first line and formulated 28 statements. These statements aimed to provide expert guidance on the selecting first- and subsequent lines of therapies as well as recommend therapies in special circumstances, such as ...
Source: Liver Cancer - June 17, 2022 Category: Cancer & Oncology Source Type: research
Exposure to Air Pollution and Survival in follow-up After Hepatocellular Carcinoma
Conclusion: Our study suggests that long-term exposure to PM2.5 and NO2 was associated with decreased survival time in patients with HCC in Taiwan. (Source: Liver Cancer)
Source: Liver Cancer - June 15, 2022 Category: Cancer & Oncology Source Type: research
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302
Conclusions: Selective cTACE appeared to have higher CR rates for local tumor control as compared to selective DEB-TACE for HCC. However, the frequency of postembolization syndrome was also significantly higher in the cTACE group than in the DEB-TACE group. Thus, to achieve CR, cTACE may be selected over DEB-TACE in patients who can be expected to tolerate postembolization syndrome. (Source: Liver Cancer)
Source: Liver Cancer - June 15, 2022 Category: Cancer & Oncology Source Type: research
Conventional or drug-eluting beads? Randomized study of chemo-embolization for hepatocellular carcinoma: JIVROSG-1302
Introduction
With the advent of effective systemic therapy, transarterial chemoembolization (TACE) is established as a highly effective locoregional treatment modality for carefully selected patients of hepatocellular carcinoma (HCC). This randomized controlled trial was conducted to clarify whether selective TACE with drug-eluting beads loaded with epirubicin (DEB-TACE) or selective conventional TACE with epirubicin-ethiodized oil (cTACE) might be more effective for obtaining complete response (CR) in patients with HCC.
Methods
Between March 2016 and May 2019, Child-Pugh class A or B patients with unresectable HCC who ...
Source: Liver Cancer - June 15, 2022 Category: Cancer & Oncology Source Type: research
Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intra-hepatic Cholangiocarcinoma: A Phase II Single-Arm Multicenter Clinical Trial
Conclusions: Treatment of SIRT followed by standard gemcitabine and cisplatin chemotherapy is feasible and effective for unresectable ICC. Further studies are required to study the optimal sequence of SIRT and chemotherapy. (Source: Liver Cancer)
Source: Liver Cancer - June 15, 2022 Category: Cancer & Oncology Source Type: research
Systemic treatments with tyrosine kinase inhibitor and platinum-based chemotherapy in patients with unresectable or metastatic hepatocholangiocarcinoma
Backgrounds and aims: Even if no systemic treatment is currently validated for unresectable hepato-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKI), and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA.
Patients and Methods: Patients with histological diagnosis of unresectable or metastatic cHCC-CCA confirmed by a centralized review (WHO classification 2019) and who received systemic treatment from 2009 to 2020 were included retrospectively in 11 centers. The outcomes of patients wit...
Source: Liver Cancer - June 14, 2022 Category: Cancer & Oncology Source Type: research
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
NA (Source: Liver Cancer)
Source: Liver Cancer - June 13, 2022 Category: Cancer & Oncology Source Type: research
APPLE News
Liver Cancer 2022;11:281 –281 (Source: Liver Cancer)
Source: Liver Cancer - June 13, 2022 Category: Cancer & Oncology Source Type: research
Impact of Antibiotics Use on Cancer-related and All-cause Mortality Among Patients Receiving Immunotherapy for Advanced Hepatocellular Carcinoma
None (Source: Liver Cancer)
Source: Liver Cancer - May 19, 2022 Category: Cancer & Oncology Source Type: research
